Skip to Content

Frequently Searched

Supported by

Up Close with Linvoseltamab

Last Updated: May 16, 2025

This section provides an overview of linvoseltamab-gcpt (LYNOZYFIC™).

Download PDF Here

Find Similar Resources:

Immunotherapy
Immunotherapy

Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings

Last Updated: 08/20/2025
 Immunotherapy

Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure

Last Updated: 08/20/2025
 Immunotherapy

Example SOPs and Documents: Bispecific T-Cell Engager Ordering and REMS Compliance

Last Updated: 08/20/2025
 Immunotherapy

Example SOPs and Documents: On-Call Responsibilities for Nurses Managing Bispecific T-Cell Engagers

Last Updated: 08/20/2025
PQI in Action

PQI in Action:  Fruquintinib (Fruzaqla®) 

Author: Florida Cancer Specialists & Research Institute | Atlanticare Cancer Care Institute
Last Updated: 08/20/2025
 PQI

PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol

Author: Sharon Zhong, PharmD, BCOP
Last Updated: 08/20/2025
 PQI

PQI: Encorafenib (Braftovi®) and Binimetinib (Mektovi®) for the Management of NSCLC

Author: Aubrey Lasko, PharmD, BCOP
Last Updated: 08/20/2025
 PQI in Action

PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2

Author: Johns Hopkins, MD | The University of Texas MD Anderson Cancer Center, TX
Last Updated: 08/20/2025
Last Updated: 08/20/2025